The stock of Ionis Pharmaceuticals Inc. (NASDAQ:IONS) increased by $0.4 on Friday to finish at $40.22, up 1.00 percent. The last five days have seen an average of 809,740 shares of common stock traded. 9 times new highs were reached in the current year, with a gain of $2.45. The average number of shares traded over the last 20 days was 1,085,305, while the average volume over the last 50 days totaled 1,275,798.
IONS stock dropped -5.72% since last month. On 07/27/23, the company’s shares reached a one-month low of $38.26. The stock touched a high of $48.82 on 07/17/23, after rallying from a low of $32.69 in 52 weeks. The price of IONS stock has risen by 6.49% or $2.45 this year, reaching a new high 9 times. Still, the stock price is down -17.62% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
IONS stock investors should be aware that Ionis Pharmaceuticals Inc. (IONS) stock had its last reported insider trading activity 13 days ago on Aug 01. On Aug 01, Director Diaz Allene M. sold 657 shares at $41.05 each. This transaction resulted in the insider making $26,970. On Jul 18, KLEIN JOSEPH III sold 3,555 shares at a price of US$42.00. After the transaction, the insider now owns 20,346 shares. Chief Executive Officer Monia Brett P had earlier sold 18,650 shares on Jul 07 for $42.25 a share. The transaction was completed for $787,953.
Valuation Metrics
Beta for the stock is 0.51. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 9.04, the price-to-book (PB) ratio of 13.45.
Financial Health
For the three months ended June 29, Ionis Pharmaceuticals Inc.’s quick ratio was 9.00, while its current ratio was 9.10, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 3.07, and the total debt to equity ratio is 3.09. As far as profitability goes, gross margin for the trailing twelve months is 98.60% percent. Ionis Pharmaceuticals Inc.’s EBITDA margin for the year ended June 29 was -66.07%, whereas its operating margin stood at -74.80% for the same period. Based on annual data, it had gross profit of $573.25 million and revenue of $587.37 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. IONS’s return on assets (ROA) during the last 12 months has been -11.40%. There was a -24.00% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -59.40%.
Earnings Surprise
According to Ionis Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended June 29, it had $8.81 million in total debt versus $2.04 billion in cash and short-term investments. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $130.52 million, while revenues fell by -237.12% to $178.56 million. It was predicted that Ionis Pharmaceuticals Inc.’s quarterly earnings would be -$0.6, but it ended up being -$0.9, beating the consensus by 33.30%. EBITDA was -$90.47 million for the quarter. At the end of Ionis Pharmaceuticals Inc.’s most recent quarter ended June 29, its liabilities totaled 2.54 billion, while its total debt was $1.49 billion. Equity owned by shareholders amounts to $143.33 million.
Technical Picture
Here’s a quick look at Ionis Pharmaceuticals Inc.’s (IONS) price momentum from a technical perspective. As of 11 August, the RSI 9-day stood at 50.72%, suggesting the stock is Neutral, with a 21.01% historical volatility rate.
The stochastic %K and %D were 48.75% and 41.65% respectively, while the average true range (ATR) was 1.05. Based on the 14-day stochastic reading of 54.60%, the RSI (14) reading is 49.30%. On the 9-day MACD Oscillator, the stock is at 0.07, and the 14-day reading is at 0.15.
Analyst Ratings
In its most recent analyst report, Citigroup raised its rating on Ionis Pharmaceuticals Inc. (NASDAQ: IONS) to a Buy. Prior to this, analysts firm rated the stock as a Neutral. Analysts have assigned Ionis Pharmaceuticals Inc. (IONS) an Overweight rating. IONS is a stock that is recommended for selling by 2 brokerage firms, while 6 companies recommend holding. The stock is underweighted by 2 analysts. Among the analysts who rate the stock, 1 rate it overweight and 11 others recommend it as a buy.
What is IONS’s price target for the next 12 months?
The current consensus forecast for the stock is between $25.00 and $88.00, with a median target price of $58.00. In analyzing these forecasts, the average price target given by analysts for Ionis Pharmaceuticals Inc. (IONS) is $50.48.
